ID   PA24E_HUMAN             Reviewed;         868 AA.
AC   Q3MJ16; B7WPN2; Q6ZSC0;
DT   25-JUL-2006, integrated into UniProtKB/Swiss-Prot.
DT   28-MAR-2018, sequence version 4.
DT   28-JUN-2023, entry version 135.
DE   RecName: Full=Cytosolic phospholipase A2 epsilon {ECO:0000303|PubMed:24413173};
DE            Short=cPLA2-epsilon {ECO:0000303|PubMed:24413173};
DE            EC=3.1.1.4 {ECO:0000250|UniProtKB:Q50L42};
DE   AltName: Full=Calcium-dependent N-acyltransferase {ECO:0000303|PubMed:29447909};
DE   AltName: Full=Phospholipase A2 group IVE;
GN   Name=PLA2G4E {ECO:0000312|HGNC:HGNC:24791};
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae;
OC   Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 2).
RC   TISSUE=Tongue;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H.,
RA   Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M.,
RA   Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K.,
RA   Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T.,
RA   Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M.,
RA   Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S.,
RA   Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H.,
RA   Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K.,
RA   Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N.,
RA   Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y.,
RA   Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K.,
RA   Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T.,
RA   Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T.,
RA   Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y.,
RA   Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H.,
RA   Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y.,
RA   Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H.,
RA   Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O.,
RA   Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [2]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=16572171; DOI=10.1038/nature04601;
RA   Zody M.C., Garber M., Sharpe T., Young S.K., Rowen L., O'Neill K.,
RA   Whittaker C.A., Kamal M., Chang J.L., Cuomo C.A., Dewar K.,
RA   FitzGerald M.G., Kodira C.D., Madan A., Qin S., Yang X., Abbasi N.,
RA   Abouelleil A., Arachchi H.M., Baradarani L., Birditt B., Bloom S.,
RA   Bloom T., Borowsky M.L., Burke J., Butler J., Cook A., DeArellano K.,
RA   DeCaprio D., Dorris L. III, Dors M., Eichler E.E., Engels R., Fahey J.,
RA   Fleetwood P., Friedman C., Gearin G., Hall J.L., Hensley G., Johnson E.,
RA   Jones C., Kamat A., Kaur A., Locke D.P., Madan A., Munson G., Jaffe D.B.,
RA   Lui A., Macdonald P., Mauceli E., Naylor J.W., Nesbitt R., Nicol R.,
RA   O'Leary S.B., Ratcliffe A., Rounsley S., She X., Sneddon K.M.B.,
RA   Stewart S., Sougnez C., Stone S.M., Topham K., Vincent D., Wang S.,
RA   Zimmer A.R., Birren B.W., Hood L., Lander E.S., Nusbaum C.;
RT   "Analysis of the DNA sequence and duplication history of human chromosome
RT   15.";
RL   Nature 440:671-675(2006).
RN   [3]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] OF 366-868.
RC   TISSUE=Heart, and Lung;
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA project:
RT   the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [4]
RP   FUNCTION, AND SUBCELLULAR LOCATION.
RX   PubMed=24413173; DOI=10.1242/jcs.136598;
RA   Capestrano M., Mariggio S., Perinetti G., Egorova A.V., Iacobacci S.,
RA   Santoro M., Di Pentima A., Iurisci C., Egorov M.V., Di Tullio G.,
RA   Buccione R., Luini A., Polishchuk R.S.;
RT   "Cytosolic phospholipase A(2)epsilon drives recycling through the clathrin-
RT   independent endocytic route.";
RL   J. Cell Sci. 127:977-993(2014).
RN   [5]
RP   FUNCTION, CATALYTIC ACTIVITY, COFACTOR, BIOPHYSICOCHEMICAL PROPERTIES, AND
RP   ACTIVITY REGULATION.
RX   PubMed=29447909; DOI=10.1016/j.bbalip.2018.02.002;
RA   Hussain Z., Uyama T., Kawai K., Binte Mustafiz S.S., Tsuboi K., Araki N.,
RA   Ueda N.;
RT   "Phosphatidylserine-stimulated production of N-acyl-
RT   phosphatidylethanolamines by Ca2+-dependent N-acyltransferase.";
RL   Biochim. Biophys. Acta 1863:493-502(2018).
RN   [6]
RP   FUNCTION, CATALYTIC ACTIVITY, ACTIVITY REGULATION, REGION, AND MUTAGENESIS
RP   OF SER-412.
RX   PubMed=30517655; DOI=10.1093/jb/mvy104;
RA   Binte Mustafiz S.S., Uyama T., Hussain Z., Kawai K., Tsuboi K., Araki N.,
RA   Ueda N.;
RT   "The role of intracellular anionic phospholipids in the production of N-
RT   acyl-phosphatidylethanolamines by cytosolic phospholipase A2 epsilon.";
RL   J. Biochem. 165:343-352(2019).
CC   -!- FUNCTION: Calcium-dependent N-acyltransferase involved in the
CC       biosynthesis of N-acyl ethanolamines (NAEs) in the brain
CC       (PubMed:29447909). Transfers the sn-1 fatty acyl chain of
CC       phosphatidylcholine (fatty acyl donor) to the amine group of
CC       phosphatidylethanolamine (fatty acyl acceptor) to generate N-acyl
CC       phosphatidylethanolamine (NAPE). Similarly can use
CC       plasmenylethanolamine as a fatty acyl acceptor to form N-acyl
CC       plasmenylethanolamine (N-Acyl-PlsEt). Both NAPE and N-Acyl-PlsEt can
CC       serve as precursors of bioactive NAEs like N-arachidonoyl
CC       phosphatidylethanolamine also called anandamide (PubMed:29447909,
CC       PubMed:30517655). Has weak phospholipase A2 and lysophospholipase
CC       activities (By similarity). Regulates intracellular membrane
CC       trafficking that requires modulation of membrane curvature as it occurs
CC       by enrichment in lysophospholipids. Promotes tubule formation involved
CC       in clathrin-independent endocytotic trafficking and cargo recycling (By
CC       similarity). {ECO:0000250|UniProtKB:Q50L42,
CC       ECO:0000269|PubMed:29447909, ECO:0000269|PubMed:30517655}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + a 1,2-diacyl-sn-
CC         glycero-3-phosphoethanolamine = a 2-acyl-sn-glycero-3-phosphocholine
CC         + H(+) + N-acyl-1,2-diacyl-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:45188, ChEBI:CHEBI:15378, ChEBI:CHEBI:57643,
CC         ChEBI:CHEBI:57875, ChEBI:CHEBI:62537, ChEBI:CHEBI:64612;
CC         Evidence={ECO:0000269|PubMed:29447909, ECO:0000269|PubMed:30517655};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45189;
CC         Evidence={ECO:0000305|PubMed:29447909, ECO:0000305|PubMed:30517655};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-
CC         hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine = 2-
CC         octadecanoyl-sn-glycero-3-phosphocholine + H(+) + N-hexadecanoyl-1,2-
CC         di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:55252, ChEBI:CHEBI:15378, ChEBI:CHEBI:73000,
CC         ChEBI:CHEBI:74986, ChEBI:CHEBI:76076, ChEBI:CHEBI:78097;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55253;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + 1-
CC         octadecanoyl-2-hexadecanoyl-sn-glycero-3-phosphocholine = 2-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+) + N-octadecanoyl-1,2-
CC         di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:55248, ChEBI:CHEBI:15378, ChEBI:CHEBI:74986,
CC         ChEBI:CHEBI:75026, ChEBI:CHEBI:76078, ChEBI:CHEBI:85292;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55249;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine +
CC         1,2-dihexadecanoyl-sn-glycero-3-phosphocholine = 2-hexadecanoyl-sn-
CC         glycero-3-phosphocholine + H(+) + N-hexadecanoyl-1,2-di-(9Z-
CC         octadecenoyl)-sn-glycero-3-phosphoethanolamine; Xref=Rhea:RHEA:45172,
CC         ChEBI:CHEBI:15378, ChEBI:CHEBI:72999, ChEBI:CHEBI:74986,
CC         ChEBI:CHEBI:76078, ChEBI:CHEBI:78097;
CC         Evidence={ECO:0000269|PubMed:29447909, ECO:0000269|PubMed:30517655};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:45173;
CC         Evidence={ECO:0000305|PubMed:29447909, ECO:0000305|PubMed:30517655};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-di-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-
CC         phosphocholine + 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-
CC         phosphoethanolamine = 2-(5Z,8Z,11Z,14Z)-eicosatetraenoyl-sn-glycero-
CC         3-phosphocholine + H(+) + N-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-1,2-di-
CC         (9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:55256, ChEBI:CHEBI:15378, ChEBI:CHEBI:60657,
CC         ChEBI:CHEBI:74986, ChEBI:CHEBI:76079, ChEBI:CHEBI:85277;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55257;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=2 1,2-di-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine =
CC         2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine + H(+) + N,1,2-
CC         tri-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine;
CC         Xref=Rhea:RHEA:55260, ChEBI:CHEBI:15378, ChEBI:CHEBI:74986,
CC         ChEBI:CHEBI:76088, ChEBI:CHEBI:85291;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:55261;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1,2-dihexadecanoyl-sn-glycero-3-phosphocholine + 1-(1Z-
CC         octadecenyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phosphoethanolamine =
CC         1-(1Z-octadecenoyl)-2-(9Z-octadecenoyl)-sn-glycero-3-phospho-N-
CC         hexadecanoyl-ethanolamine + 2-hexadecanoyl-sn-glycero-3-
CC         phosphocholine + H(+); Xref=Rhea:RHEA:63592, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:72999, ChEBI:CHEBI:76078, ChEBI:CHEBI:78340,
CC         ChEBI:CHEBI:138663; Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:63593;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=a 1,2-diacyl-sn-glycero-3-phosphocholine + H2O = a 1-acyl-sn-
CC         glycero-3-phosphocholine + a fatty acid + H(+); Xref=Rhea:RHEA:15801,
CC         ChEBI:CHEBI:15377, ChEBI:CHEBI:15378, ChEBI:CHEBI:28868,
CC         ChEBI:CHEBI:57643, ChEBI:CHEBI:58168; EC=3.1.1.4;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:15802;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-2-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-
CC         3-phosphocholine + H2O = (5Z,8Z,11Z,14Z)-eicosatetraenoate + 1-
CC         hexadecanoyl-sn-glycero-3-phosphocholine + H(+);
CC         Xref=Rhea:RHEA:40427, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:32395, ChEBI:CHEBI:72998, ChEBI:CHEBI:73003;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40428;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=1-hexadecanoyl-sn-glycero-3-phosphocholine + H2O = H(+) +
CC         hexadecanoate + sn-glycerol 3-phosphocholine; Xref=Rhea:RHEA:40435,
CC         ChEBI:CHEBI:7896, ChEBI:CHEBI:15377, ChEBI:CHEBI:15378,
CC         ChEBI:CHEBI:16870, ChEBI:CHEBI:72998;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC       PhysiologicalDirection=left-to-right; Xref=Rhea:RHEA:40436;
CC         Evidence={ECO:0000250|UniProtKB:Q50L42};
CC   -!- COFACTOR:
CC       Name=Ca(2+); Xref=ChEBI:CHEBI:29108; Evidence={ECO:0000255|PROSITE-
CC         ProRule:PRU00041, ECO:0000269|PubMed:29447909};
CC   -!- ACTIVITY REGULATION: Stimulated by cytosolic Ca(2+). Stimulated by
CC       anionic phospholipids such as phosphatidylserines, phosphatidates and
CC       phosphatidylinositols. {ECO:0000269|PubMed:29447909,
CC       ECO:0000269|PubMed:30517655}.
CC   -!- BIOPHYSICOCHEMICAL PROPERTIES:
CC       pH dependence:
CC         Optimum pH is 8. {ECO:0000269|PubMed:29447909};
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytosol
CC       {ECO:0000250|UniProtKB:Q50L42}. Early endosome membrane
CC       {ECO:0000250|UniProtKB:Q50L42}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q50L42}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q50L42}. Lysosome membrane
CC       {ECO:0000250|UniProtKB:Q50L42}; Peripheral membrane protein
CC       {ECO:0000250|UniProtKB:Q50L42}; Cytoplasmic side
CC       {ECO:0000250|UniProtKB:Q50L42}. Cell membrane
CC       {ECO:0000250|UniProtKB:Q50L42}; Peripheral membrane protein;
CC       Cytoplasmic side {ECO:0000250|UniProtKB:Q50L42}. Note=Targeted to
CC       clathrin-independent endocytotic vesicles through binding to
CC       phosphoinositides, especially phosphatidylinositol 4,5-bisphosphates.
CC       {ECO:0000250|UniProtKB:Q50L42}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=2;
CC       Name=1;
CC         IsoId=Q3MJ16-3; Sequence=Displayed;
CC       Name=2;
CC         IsoId=Q3MJ16-2; Sequence=VSP_019883;
CC   -!- DOMAIN: The N-terminal C2 domain associates with lipid membranes upon
CC       calcium binding. It modulates enzyme activity by presenting the active
CC       site to its substrate in response to elevations of cytosolic Ca(2+) (By
CC       similarity). {ECO:0000250}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; AK127558; BAC87034.1; -; mRNA.
DR   EMBL; AC039056; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; BC101584; AAI01585.2; -; mRNA.
DR   EMBL; BC101612; AAI01613.2; -; mRNA.
DR   CCDS; CCDS55962.1; -. [Q3MJ16-3]
DR   RefSeq; NP_001193599.1; NM_001206670.1. [Q3MJ16-3]
DR   RefSeq; XP_011519540.1; XM_011521238.1. [Q3MJ16-2]
DR   AlphaFoldDB; Q3MJ16; -.
DR   SMR; Q3MJ16; -.
DR   BioGRID; 125832; 31.
DR   IntAct; Q3MJ16; 3.
DR   STRING; 9606.ENSP00000382434; -.
DR   ChEMBL; CHEMBL3831242; -.
DR   PhosphoSitePlus; Q3MJ16; -.
DR   BioMuta; PLA2G4E; -.
DR   DMDM; 325511387; -.
DR   EPD; Q3MJ16; -.
DR   jPOST; Q3MJ16; -.
DR   MassIVE; Q3MJ16; -.
DR   PeptideAtlas; Q3MJ16; -.
DR   ProteomicsDB; 61802; -. [Q3MJ16-2]
DR   ProteomicsDB; 6312; -.
DR   Antibodypedia; 42114; 101 antibodies from 22 providers.
DR   DNASU; 123745; -.
DR   Ensembl; ENST00000399518.3; ENSP00000382434.3; ENSG00000188089.14. [Q3MJ16-3]
DR   GeneID; 123745; -.
DR   KEGG; hsa:123745; -.
DR   UCSC; uc021sjp.2; human.
DR   AGR; HGNC:24791; -.
DR   CTD; 123745; -.
DR   DisGeNET; 123745; -.
DR   GeneCards; PLA2G4E; -.
DR   HGNC; HGNC:24791; PLA2G4E.
DR   HPA; ENSG00000188089; Tissue enriched (skin).
DR   neXtProt; NX_Q3MJ16; -.
DR   OpenTargets; ENSG00000188089; -.
DR   VEuPathDB; HostDB:ENSG00000188089; -.
DR   eggNOG; KOG1028; Eukaryota.
DR   eggNOG; KOG1325; Eukaryota.
DR   GeneTree; ENSGT01030000234606; -.
DR   InParanoid; Q3MJ16; -.
DR   OMA; SFENTQR; -.
DR   OrthoDB; 4250045at2759; -.
DR   PhylomeDB; Q3MJ16; -.
DR   TreeFam; TF325228; -.
DR   PathwayCommons; Q3MJ16; -.
DR   Reactome; R-HSA-1482788; Acyl chain remodelling of PC.
DR   Reactome; R-HSA-1482801; Acyl chain remodelling of PS.
DR   Reactome; R-HSA-1482839; Acyl chain remodelling of PE.
DR   Reactome; R-HSA-1482922; Acyl chain remodelling of PI.
DR   Reactome; R-HSA-1483115; Hydrolysis of LPC.
DR   SignaLink; Q3MJ16; -.
DR   BioGRID-ORCS; 123745; 19 hits in 1145 CRISPR screens.
DR   GenomeRNAi; 123745; -.
DR   Pharos; Q3MJ16; Tbio.
DR   PRO; PR:Q3MJ16; -.
DR   Proteomes; UP000005640; Chromosome 15.
DR   RNAct; Q3MJ16; protein.
DR   Bgee; ENSG00000188089; Expressed in skin of leg and 45 other tissues.
DR   GO; GO:0005829; C:cytosol; IBA:GO_Central.
DR   GO; GO:0031901; C:early endosome membrane; ISS:UniProtKB.
DR   GO; GO:0005765; C:lysosomal membrane; ISS:UniProtKB.
DR   GO; GO:0005886; C:plasma membrane; ISS:UniProtKB.
DR   GO; GO:0005509; F:calcium ion binding; IBA:GO_Central.
DR   GO; GO:0047498; F:calcium-dependent phospholipase A2 activity; IBA:GO_Central.
DR   GO; GO:0005544; F:calcium-dependent phospholipid binding; IBA:GO_Central.
DR   GO; GO:0016410; F:N-acyltransferase activity; IDA:UniProtKB.
DR   GO; GO:0005547; F:phosphatidylinositol-3,4,5-trisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0043325; F:phosphatidylinositol-3,4-bisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0080025; F:phosphatidylinositol-3,5-bisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0032266; F:phosphatidylinositol-3-phosphate binding; ISS:UniProtKB.
DR   GO; GO:0005546; F:phosphatidylinositol-4,5-bisphosphate binding; ISS:UniProtKB.
DR   GO; GO:0070273; F:phosphatidylinositol-4-phosphate binding; ISS:UniProtKB.
DR   GO; GO:0010314; F:phosphatidylinositol-5-phosphate binding; ISS:UniProtKB.
DR   GO; GO:0008970; F:phospholipase A1 activity; TAS:Reactome.
DR   GO; GO:0046475; P:glycerophospholipid catabolic process; IBA:GO_Central.
DR   GO; GO:0070292; P:N-acylphosphatidylethanolamine metabolic process; IDA:UniProtKB.
DR   GO; GO:0036149; P:phosphatidylinositol acyl-chain remodeling; TAS:Reactome.
DR   GO; GO:2001137; P:positive regulation of endocytic recycling; IMP:UniProtKB.
DR   CDD; cd04036; C2_cPLA2; 1.
DR   CDD; cd07201; cPLA2_Grp-IVB-IVD-IVE-IVF; 1.
DR   Gene3D; 2.60.40.150; C2 domain; 1.
DR   Gene3D; 3.40.1090.10; Cytosolic phospholipase A2 catalytic domain; 1.
DR   InterPro; IPR016035; Acyl_Trfase/lysoPLipase.
DR   InterPro; IPR041847; C2_cPLA2.
DR   InterPro; IPR000008; C2_dom.
DR   InterPro; IPR035892; C2_domain_sf.
DR   InterPro; IPR040723; cPLA2_C2.
DR   InterPro; IPR002642; LysoPLipase_cat_dom.
DR   PANTHER; PTHR10728; CYTOSOLIC PHOSPHOLIPASE A2; 1.
DR   PANTHER; PTHR10728:SF24; CYTOSOLIC PHOSPHOLIPASE A2 EPSILON; 1.
DR   Pfam; PF00168; C2; 1.
DR   Pfam; PF18695; cPLA2_C2; 1.
DR   Pfam; PF01735; PLA2_B; 1.
DR   SMART; SM00239; C2; 1.
DR   SMART; SM00022; PLAc; 1.
DR   SUPFAM; SSF49562; C2 domain (Calcium/lipid-binding domain, CaLB); 1.
DR   SUPFAM; SSF52151; FabD/lysophospholipase-like; 1.
DR   PROSITE; PS50004; C2; 1.
DR   PROSITE; PS51210; PLA2C; 1.
PE   1: Evidence at protein level;
KW   Alternative splicing; Calcium; Cell membrane; Cytoplasm; Endosome;
KW   Hydrolase; Lipid degradation; Lipid metabolism; Lysosome; Membrane;
KW   Metal-binding; Phosphoprotein; Reference proteome; Transferase.
FT   CHAIN           1..868
FT                   /note="Cytosolic phospholipase A2 epsilon"
FT                   /id="PRO_0000247025"
FT   DOMAIN          46..170
FT                   /note="C2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   DOMAIN          324..856
FT                   /note="PLA2c"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00555"
FT   REGION          1..46
FT                   /note="Disordered"
FT                   /evidence="ECO:0000256|SAM:MobiDB-lite"
FT   REGION          857..868
FT                   /note="Required for localization at membrane structures"
FT                   /evidence="ECO:0000269|PubMed:30517655"
FT   ACT_SITE        412
FT                   /note="Nucleophile"
FT                   /evidence="ECO:0000250"
FT   ACT_SITE        700
FT                   /note="Proton acceptor"
FT                   /evidence="ECO:0000250"
FT   BINDING         84
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         84
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         90
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         140
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         140
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         142
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="1"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         142
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   BINDING         148
FT                   /ligand="Ca(2+)"
FT                   /ligand_id="ChEBI:CHEBI:29108"
FT                   /ligand_label="2"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00041"
FT   MOD_RES         800
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:Q50L42"
FT   VAR_SEQ         1..376
FT                   /note="Missing (in isoform 2)"
FT                   /evidence="ECO:0000303|PubMed:14702039"
FT                   /id="VSP_019883"
FT   VARIANT         400
FT                   /note="N -> S (in dbSNP:rs4924595)"
FT                   /id="VAR_027052"
FT   VARIANT         693
FT                   /note="A -> T (in dbSNP:rs8030775)"
FT                   /id="VAR_027053"
FT   MUTAGEN         412
FT                   /note="S->A: Impairs localization at membrane structures
FT                   and N-acyl transferase activity."
FT                   /evidence="ECO:0000269|PubMed:30517655"
FT   CONFLICT        389
FT                   /note="M -> V (in Ref. 1; BAC87034)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        502
FT                   /note="A -> P (in Ref. 1; BAC87034)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        690
FT                   /note="T -> A (in Ref. 1; BAC87034)"
FT                   /evidence="ECO:0000305"
FT   CONFLICT        765
FT                   /note="C -> Y (in Ref. 1; BAC87034)"
FT                   /evidence="ECO:0000305"
SQ   SEQUENCE   868 AA;  99190 MW;  F9A6F33880A5409F CRC64;
     MSLQASEGCP GLGTNVFVPQ SPQTDEEGSR SGRSFSEFED TQDLDTPGLP PFCPMAPWGS
     EEGLSPCHLL TVRVIRMKNV RQADMLSQTD CFVSLWLPTA SQKKLRTRTI SNCPNPEWNE
     SFNFQIQSRV KNVLELSVCD EDTVTPDDHL LTVLYDLTKL CFRKKTHVKF PLNPQGMEEL
     EVEFLLEESP SPPETLVTNG VLVSRQVSCL EVHAQSRRRR KREKMKDLLV MVNESFENTQ
     RVRPCLEPCC PTSACFQTAA CFHYPKYFQS QVHVEVPKSH WSCGLCCRSR KKGPISQPLD
     CLSDGQVMTL PVGESYELHM KSTPCPETLD VRLGFSLCPA ELEFLQKRKV VVAKALKQVL
     QLEEDLQEDE VPLIAIMATG GGTRSMTSMY GHLLGLQKLN LLDCASYITG LSGATWTMAT
     LYRDPDWSSK NLEPAIFEAR RHVVKDKLPS LFPDQLRKFQ EELRQRSQEG YRVTFTDFWG
     LLIETCLGDE RNECKLSDQR AALSCGQNPL PIYLTINVKD DVSNQDFREW FEFSPYEVGL
     QKYGAFIPSE LFGSEFFMGR LVKRIPESRI CYMLGLWSSI FSLNLLDAWN LSHTSEEFFH
     RWTREKVQDI EDEPILPEIP KCDANILETT VVIPGSWLSN SFREILTHRS FVSEFHNFLS
     GLQLHTNYLQ NGQFSRWKDT VLDGFPNQLT ESANHLCLLD TAFFVNSSYP PLLRPERKAD
     LIIHLNYCAG SQTKPLKQTC EYCTVQNIPF PKYELPDENE NLKECYLMEN PQEPDAPIVT
     FFPLINDTFR KYKAPGVERS PEELEQGQVD IYGPKTPYAT KELTYTEATF DKLVKLSEYN
     ILNNKDTLLQ ALRLAVEKKK RLKGQCPS
//
